Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With PBRM1, SETD2, BAP1, or KDM5C Mutations

被引:5
|
作者
Liu, Yang [1 ]
Li, Yunhao [2 ]
Xu, Haimin [1 ]
Zhou, Luting [1 ,3 ]
Yang, Xiaoqun [1 ,3 ]
Wang, Chaofu [1 ,3 ]
机构
[1] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Pathol, Sch Med, Shanghai, Peoples R China
[2] China Med Univ, Clin Coll 1, Shenyang, Peoples R China
[3] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Pathol, Number197,Ruijin Er Rd, Shanghai 200025, Peoples R China
基金
中国国家自然科学基金;
关键词
clear cell renal cell carcinoma; PBRM1; BAP1; KDM5C; SETD2; morphology;
D O I
10.1177/10668969231157317
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The last decade has seen great advances in genomic profiling and prognosis-associated factors of clear cell renal cell carcinoma (RCC), the most common entity in kidney cancer. Following VHL, PBRM1, SETD2, BAP1, and KDM5C have been validated as the most common co-occurring gene mutations in clear cell RCC by multicenter studies. However, the morphological features of clear cell RCC with co-occurring gene mutations remain unclear. In this study, we presented 20 clear cell RCCs that underwent next-generation sequencing, of which 1 tumor was reclassified as ELOC-mutated RCC. PBRM1, SETD2, BAP1, and KDM5C were the most common mutations, following VHL. Morphologically, clear cell RCC with PBRM1 or KDM5C mutation usually displayed a low-grade pattern. Cystic changes and hyalinized stroma were often observed. The Ki67 index was <10%. These observations indicated good prognosis. However, mutated SETD2 may increase the malignancy of clear cell RCC with PBRM1 mutation. Two clear cell RCCs with mutated PBRM1 and SETD2 developed local or distant metastases. Clear cell RCC with BAP1 mutations always had high-grade patterns, and rhabdoid differentiation was also observed, indicating that BAP1 mutation was associated with poor outcomes. Papillary architecture was often a feature of BAP1 mutation, which is uncommon in clear cell RCC. PDL1 was positive in only one tumor with BAP1 mutation, and the positivity rate was limited to 5%. B7H3 was negative in all tumors. Morphologic findings in this small cohort may suggest why PBRM1 mutation does not correlate with decreased survival, whereas BAP1 mutation usually predicts poor outcomes.
引用
收藏
页码:1485 / 1494
页数:10
相关论文
共 50 条
  • [1] PBRM1, SETD2 and BAP1 — the trinity of 3p in clear cell renal cell carcinoma
    Joseph Walton
    Keith Lawson
    Panagiotis Prinos
    Antonio Finelli
    Cheryl Arrowsmith
    Laurie Ailles
    Nature Reviews Urology, 2023, 20 : 96 - 115
  • [2] Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma
    Gossage, Lucy
    Murtaza, Muhammed
    Slatter, Andrew F.
    Lichtenstein, Conrad P.
    Warren, Anne
    Haynes, Beverley
    Marass, Francesco
    Roberts, Ian
    Shanahan, Susan J.
    Claas, Andreas
    Dunham, Andrew
    May, Andrew P.
    Rosenfeld, Nitzan
    Forshew, Tim
    Eisen, Tim
    GENES CHROMOSOMES & CANCER, 2014, 53 (01): : 38 - 51
  • [3] Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma
    Bihr, Svenja
    Ohashi, Riuko
    Moore, Ariane L.
    Ruschoff, Jan H.
    Beisel, Christian
    Hermanns, Thomas
    Mischo, Axel
    Corro, Claudia
    Beyer, Jorg
    Beerenwinkel, Niko
    Moch, Holger
    Schraml, Peter
    NEOPLASIA, 2019, 21 (02): : 247 - 256
  • [4] BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies
    Piva, Francesco
    Santoni, Matteo
    Matrana, Marc R.
    Satti, Suma
    Giulietti, Matteo
    Occhipinti, Giulia
    Massari, Francesco
    Cheng, Liang
    AntonioLopez-Beltran
    Scarpelli, Marina
    Principato, Giovanni
    Cascinu, Stefano
    Montironi, Rodolfo
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2015, 15 (09) : 1201 - 1210
  • [5] PBRM1, SETD2 and BAP1-the trinity of 3p in clear cell renal cell carcinoma
    Walton, Joseph
    Lawson, Keith
    Prinos, Panagiotis
    Finelli, Antonio
    Arrowsmith, Cheryl
    Ailles, Laurie
    NATURE REVIEWS UROLOGY, 2023, 20 (02) : 96 - 115
  • [6] Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma
    Piva, Francesco
    Giulietti, Matteo
    Occhipinti, Giulia
    Santoni, Matteo
    Massari, Francesco
    Sotte, Valeria
    Iacovelli, Roberto
    Burattini, Luciano
    Santini, Daniele
    Montironi, Rodolfo
    Cascinu, Stefano
    Principato, Giovanni
    ONCOTARGET, 2015, 6 (31) : 32161 - 32168
  • [7] Analysis of gene expression changes as a function of PBRM1, BAP1, and SETD2 mutation status clear cell renal cell carcinoma in TCGA tumors
    Abbosh, Philip H.
    Ibragimova, Ilsiya
    Slifker, Michael
    Cairns, Paul
    CANCER RESEARCH, 2015, 75
  • [8] PBRM1 and BAP1 expression in renal cell carcinoma
    Kuthi, L.
    Fallmann, E.
    Jenei, A.
    Posfai, B.
    Maraz, A.
    VIRCHOWS ARCHIV, 2018, 473 : S44 - S44
  • [9] Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression
    Joseph, Richard W.
    Kapur, Payal
    Serie, Daniel J.
    Parasramka, Mansi
    Ho, Thai H.
    Cheville, John C.
    Frenkel, Eugene
    Parker, Alexander S.
    Brugarolas, James
    JOURNAL OF UROLOGY, 2016, 195 (01): : 180 - 187
  • [10] ADVERSE OUTCOMES IN CLEAR CELL RENAL CELL CARCINOMA WITH MUTATIONS OF EPIGENETIC REGULATORS BAP1 AND SETD2
    Hakimi, A. Ari
    Ostrovnaya, Irina
    Reva, Boris
    Schultz, Nikolaus
    Chen, Ying-Bei
    Gonen, Mithat
    Liu, Han
    Takeda, Shugaku
    Tickoo, Satish K.
    Voss, Martin H.
    Cheng, Emily H.
    Reuter, Victor E.
    Motzer, Robert J.
    Russo, Paul
    Hsieh, James J.
    JOURNAL OF UROLOGY, 2013, 189 (04): : E438 - E438